Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

  • Wen, Jing-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Li, Mai (Department of Biotechnology, Guangdong Food and Drug Vocational College) ;
  • Li, Xing (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Chen, Jie (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Lin, Qu (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Ma, Xiao-Kun (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Dong, Min (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Wei, Li (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Chen, Zhan-Hong (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Wu, Xiang-Yuan (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Nasal-type extranodal natural killer (NK)/T-cell lymphoma (ENKL) is a highly invasive cancer with a poor prognosis. More effective and safer treatment regimens for ENKL are needed. Pegaspargase (PEG-Asp) has a similar mechanism of action to L-asparaginase (L-Asp), but presents lower antigenicity. The aim of the present research was to evaluate the safety profile and the latent efficacy of a PEG-Asp-based treatment regimen in patients with ENKL. Data collected from 20 patients with histologically confirmed ENKL, admitted to the Third Affiliated Hospital of Sun Yat-Sen University from January 2009 to August 2013, were included in the study. All patients received $2500IU/m^2$/IM PEG-Asp on day 1 of every 21-day treatment cycle. Patients received combination chemotherapy with CHOP (n=5), EPOCH (n=7), GEMOX (n=7) or CHOP with bleomycin (n=1). After 2-5 treatment cycles (median, 4 cycles) of PEG-Asp-based chemotherapy, five patients (25%) showed a complete response (CR), and the overall response rate (ORR) was 60%. Grade 3/4 neutropenia occurred in fourteen patients (70%). Grade 3 alanine aminotransferase (ALT) elevation was observed in two. Grade 1-2 non-hematological toxicity consisted of activated partial thromboplastin time (APTT) elongation (n=9), hypofibrinogenemia (n=6), hypoproteinemia (n=17), hyperglycemia (n=3), and nausea (n=6). No allergic reactions were detected. No treatment related death was reported. Our results suggested that PEG-Asp-based chemotherapy presented an acceptable tolerance and a potential short-term outcome in patients with nasal-type ENKL.

Keywords

References

  1. Alfieri DR (1995). Pegaspargase. Pediatr Nurs, 21, 471-4, 490.
  2. Alvarez OA, Zimmerman G (2000). Pegaspargase-induced pancreatitis. Med Pediatr Oncol, 34, 200-5. https://doi.org/10.1002/(SICI)1096-911X(200003)34:3<200::AID-MPO7>3.0.CO;2-T
  3. Avramis VI, Sencer S, Periclou AP, et al (2002). A randomized comparison native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 99, 1986-94. https://doi.org/10.1182/blood.V99.6.1986
  4. Binesh F, Akhavan A, Behniafard N, et al (2014). Clinicopathologic and survival characteristics of childhood and adolescent non Hodgkin's lymphoma in Yazd, Iran. Asian Pac J Cancer Prev, 15, 1585-8. https://doi.org/10.7314/APJCP.2014.15.4.1585
  5. Chakrabarti S, Sarkar S, Goswami BK, et al (2010). Hodgkin's and Non-Hodgkin's lymphomas in an Indian rural medical institution: comparative clinicopathologic analysis. Asian Pac J Cancer Prev, 11, 1605-8.
  6. Cheson BD, Pfistner B, Juweid ME, et al (2009). Revised response criteria for malignant lymphoma. J Clin Oncol, 25, 579-86.
  7. Colombat P, Salles G, Brousse N, et al (2001). Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 97, 101-6. https://doi.org/10.1182/blood.V97.1.101
  8. Dinndorf PA, Gootenberg J, Cohen MH, et al (2007). FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist, 12, 991-8. https://doi.org/10.1634/theoncologist.12-8-991
  9. Graham ML (2003). Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev, 55, 1293-302. https://doi.org/10.1016/S0169-409X(03)00110-8
  10. He X, Chen Z, Fu T, et al (2014). Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer, 14, 153. https://doi.org/10.1186/1471-2407-14-153
  11. Huang X, Sun Q, Fu H, et al (2014). Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China. Pathol Res Pract, 210, 351-6. https://doi.org/10.1016/j.prp.2014.02.004
  12. Jaccard A, Petit B, Girault S, et al (2009). L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol, 20, 110-6.
  13. Jaccard A, Gachard N, Marin B, et al (2011). Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood, 117, 1834-9. https://doi.org/10.1182/blood-2010-09-307454
  14. Kim SJ, Kim BS, Choi CW, et al (2007). Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol, 18, 1382-7. https://doi.org/10.1093/annonc/mdm183
  15. Lee J, Suh C, Park YH, et al (2006). Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol, 24, 612-8. https://doi.org/10.1200/JCO.2005.04.1384
  16. Li C C, Tien H F, Tang J L, et al (2004). Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer, 100, 366-75. https://doi.org/10.1002/cncr.11908
  17. Li YX, Yao B, Jin J, et al (2006). Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol, 24, 181-9. https://doi.org/10.1200/JCO.2005.03.2573
  18. Li L, Zhang C, Zhang L, et al (2014). Efficacy of a pegaspargasebased regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma. Neoplasma, 61, 225-32. https://doi.org/10.4149/neo_2014_029
  19. Lin N, Song Y, Zheng W, et al (2013). A prospective phase II study of L-asparaginase CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol, 6, 44. https://doi.org/10.1186/1756-8722-6-44
  20. Liu J, Song B, Fan T, et al (2011). Pathological and clinical characteristics of 1, 248 non-Hodgkin's lymphomas from a regional cancer hospital in Shandong, China. Asian Pac J Cancer Prev, 12, 3055-61.
  21. Muss H .B, Spell N, Scudiery D, et al (1990). A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs, 8, 125-30.
  22. Msdryyi R, Pession A (2009). First-line treatment of acute lymphoblastic leukemia with pegasparaginase. Biologics, 3, 359-68.
  23. Obama K, Tara M, Niina K (2003). L-asparaginase therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol, 78, 248-50. https://doi.org/10.1007/BF02983802
  24. Padhi S, Paul TR, Challa S, et al (2012). Primary extra nodal non Hodgkin lymphoma: a 5 year retrospective analysis. Asian Pac J Cancer Prev, 13, 4889-95. https://doi.org/10.7314/APJCP.2012.13.10.4889
  25. Reyes VE Jr, Al-Saleem T, Robu VG, et al (2010). Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature. Leuk Res, 34, 50-4. https://doi.org/10.1016/j.leukres.2009.06.028
  26. Silverman LB, Supko JG, Stevenson KE, et al (2010). Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood, 115, 1351-3. https://doi.org/10.1182/blood-2009-09-245951
  27. Tahmasby B, Marnani AB, Maleki M, et al (2013). Blood malignancies in Mazandaran province of Iran. Asian Pac J Cancer Prev, 14, 1053-6. https://doi.org/10.7314/APJCP.2013.14.2.1053
  28. Teske E, Rutteman GR, van Heerde P, et al (1990). Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma. Eur J Cancer, 26, 891-5. https://doi.org/10.1016/0277-5379(90)90193-W
  29. The Cooperation Group of Phase II Clinical Trial of PEG-Asp (2008). Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi, 29, 29-33.
  30. Tulpule A, Espina B, Palmer M (1998). Preliminary results of PEG-L-asparaginase (Oncaspar) in the treatment of relapsed / refractory AIDS-related lymphomas. Blood, 92 (Suppl 1), 240.
  31. Wang TT, Wang Z (2009). Recent advances on extranodal NK/T-cell lymphoma of nasal type. Zhonghua Xue Ye Xue Za Zhi, 17, 1624-8.
  32. Woo MH, Hak LJ, Storm MC, et al (2000). Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol, 18, 1525-32.
  33. Xu W, Fan L, Miao Y, et al (2014). Distribution of lymphomas subtypes in Jiangsu Province: A multicenter analysis of 5 147 cases. Zhonghua Xue Ye Xue Za Zhi, 35, 300-3.
  34. Yamaguchi M, Kwong YL, Kim WS, et al (2011). Phase II Study of SMILE Chemotherapy for newly diagnosed stage IV relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group Study. J Clin Oncol, 29, 4410-6. https://doi.org/10.1200/JCO.2011.35.6287
  35. Yasuda H, Sugimoto K, Imai H, et al (2009). Expression levels of apoptosis-related proteins and Ki-67 in nasal NK/T-cell lymphoma. Eur J Haematol, 82, 39-45. https://doi.org/10.1111/j.1600-0609.2008.01152.x
  36. Yong W, Zheng W, Zhu J, et al (2006). Midline NK/T-cell lymphoma nasal type: treatment outcome, the effect of Lasparaginase based regimen and prognostic factors. Hematol Oncol, 78, 163-76.
  37. Yong W, Zheng W, Zhu J, et al (2009). L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol, 88, 647-52. https://doi.org/10.1007/s00277-008-0669-3
  38. Zhang J, Zhu MY, Wang L, et al (2013). "Sandwich" chemotherapy (CT) with radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas. Asian Pac J Cancer Prev, 14, 4061-6. https://doi.org/10.7314/APJCP.2013.14.7.4061

Cited by

  1. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study vol.102, pp.2, 2015, https://doi.org/10.1007/s12185-015-1809-x
  2. Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4515
  3. Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma vol.33, pp.1, 2017, https://doi.org/10.1007/s12288-016-0670-2
  4. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study vol.100, pp.3, 2018, https://doi.org/10.1111/ejh.13004
  5. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-4782-y